Microbiologics expands virology capabilities for SARS-CoV-2 with new BSL-3 laboratory at its San Diego facility

FacebookFacebookTwitterTwitterEmailEmailLinkedInLinkedInWhatsAppWhatsAppMessengerMessengerFlipboardFlipboardGmailGmailTelegramTelegramShareShare

SAN DIEGO, Aug. 3, 2020 /PRNewswire/ — Microbiologics announced today that it has recently completed renovations of the virology services laboratory in its San Diego location. With completion of the renovation, Microbiologics has expanded its custom virology solutions to include Biosafety Level 3 (BSL-3) antiviral services. With these new capabilities, Microbiologics has launched a menu of cell-based services for SARS-CoV-2 to assist assay developers, evaluate therapeutic solutions and vaccines, and provide inactivated intact virus to researchers and diagnostic companies.

Microbiologics has also expanded its viral capabilities to include reverse genetics systems to create recombinant viruses, increased in-vitro assay capabilities, including cytopathic effect screening, hemagglutination-inhibition testing (HAI), neutralization assays, and yield-reduction assays. The newly renovated space also allows for increased capacity for viral propagation of high-titer stock materials. Microbiologics has also recently completed its process for ISO 13485 accreditation at the San Diego Facility.

Additional information about the complete virology services offered at Microbiologics is available by email at VirologyServices@microbiologics.com.

Visit microbiologics.com/virology to learn more.

About Microbiologics

Microbiologics, the leading global provider of infectious disease biomaterials. Microbiologics has provided clinical, food, water, pharmaceutical and cosmetic laboratories with reliable, ready-to-use microbial reference materials for nearly 50 years. The company has a distribution network that reaches more than 140 countries worldwide.

Microbiologics acquired San Diego based Virapur in 2017 expanding its research and development support services to therapeutics, vaccines and gene therapy, as well as broaden its viral molecular controls portfolio.

Karin Pauly
Microbiologics
1.800.599.2847
marketing@microbiologics.com

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/microbiologics-expands-virology-capabilities-for-sars-cov-2-with-new-bsl-3-laboratory-at-its-san-diego-facility-301104901.html

SOURCE Microbiologics

Staff

Recent Posts

Assembly Biosciences Presents Data Highlighting Recurrent Genital Herpes Program at STI & HIV 2025 World Congress and International Herpesvirus Workshop

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel…

1 day ago

ISS Recommends Shareholders Vote FOR the Merger between Regional Health Properties, Inc. and SunLink Health Systems, Inc.

Atlanta, GA., July 25, 2025 (GLOBE NEWSWIRE) -- Regional Health Properties, Inc. (“Regional”) (OTCBQ: RHEP)…

1 day ago

PharmAla Issues Q3 Financial Statements

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”)…

1 day ago

Calidi announces Reverse Stock Split, expected to begin trading on a 1-for-12 split adjusted basis on August 5, 2025

SAN DIEGO, July 25, 2025 (GLOBE NEWSWIRE) -- Calidi Biotherapeutics, Inc. (“Calidi” or the “Company”)…

1 day ago

Portage Biotech Reports Results for Fiscal Year Ended March 31, 2025

DOVER, Del., July 25, 2025 (GLOBE NEWSWIRE) -- Portage Biotech Inc. (“Portage” or the “Company”)…

1 day ago

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the…

1 day ago